Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emugrobart + tirzepatide
- Development stage
- Phase 2
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
Emugrobart + tirzepatide is an investigational combination regimen pairing emugrobart (GYM329, RO7204239), a subcutaneously administered monoclonal antibody that binds latent myostatin, with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Roche, the combination was evaluated in the Phase 2 GYMINDA trial for the treatment of obesity and overweight in adults without diabetes, with the goal of preserving lean muscle mass during tirzepatide-induced weight loss. However, Roche discontinued the obesity program in September 2026 after an interim analysis concluded that achieving clinically meaningful weight loss was unlikely. Following the discontinuation, rights to emugrobart reverted to Chugai Pharmaceutical.
- Other names
- GYM329 + LY3298176GYM329 + tirzepatideRG6237 + LY3298176RG6237 + tirzepatideRO7204239 + LY3298176RO7204239 + tirzepatideemugrobart + LY3298176
02
Targets
Beyond the preview
Go deeper on emugrobart + tirzepatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emugrobart + tirzepatide.